Both the nanobody and its derivatives stimulated substantial phagocytosis of MCF7 and U937 tumor cell lines via the primary macrophages ex vivo, thus validating the affinity and functional activity of the derived anti-CD47 nanobody. Here, CD47 is linked to neoplasm.